Low-Dose of Intrapulmonary Pirfenidone Improves Human Transforming Growth Factorβ1-Driven Lung Fibrosis

Idiopathic pulmonary fibrosis is a chronic, progressive, and lethal lung disease of unknown etiology. Antifibrotic drugs, including pirfenidone, are currently used for the treatment of the disease. The oral administration of pirfenidone is an effective therapy, as demonstrated by several clinical tr...

詳細記述

保存先:
書誌詳細
出版年:Front Pharmacol
主要な著者: Okano, Tomohito, Kobayashi, Tetsu, Yasuma, Taro, D’Alessandro-Gabazza, Corina N., Toda, Masaaki, Fujimoto, Hajime, Nakahara, Hiroki, Okano, Yuko, Takeshita, Atsuro, Nishihama, Kota, Saiki, Haruko, Tomaru, Atsushi, Fridman D’Alessandro, Valeria, Ishida, Satoru, Sugimoto, Hiromi, Takei, Yoshiyuki, Gabazza, Esteban C.
フォーマット: Artigo
言語:Inglês
出版事項: Frontiers Media S.A. 2020
主題:
Pharmacology
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC7774321/
https://ncbi.nlm.nih.gov/pubmed/33390975
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fphar.2020.593620
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料